Roche’s Akt inhibitor’s first pivotal result, in first-line prostate cancer, is at best a partial success and at worst an irrelevance.
As durability continues to fog the future for Biomarin’s gene therapy, Pfizer and Sangamo keep up the pressure.
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.
Inventiva’s mid-stage win has revived hopes for PPAR agonists in the liver disease, although safety questions remain.
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
Dupixent might face a threat to its lead in dermatitis – but this comes from Pfizer, not Leo.
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.